Development of germline-humanized antibodies neutralizing botulinum neurotoxin A and B

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Miethe, Sebastian ^a   Mazuet, Christelle ^b   Liu, Yvonne ^c   Tierney, Robert ^c   Rasetti Escargueil, Christine ^c   Avril, Arnaud ^d   Frenzel, André ^a   Thullier, Philippe ^d   Pelat, Thibaut ^d,f   Urbain, Remi ^e,g   Fontayne, Alexandre ^e   Sesardic, Dorothea ^c   Hust, Michael ^a   Popoff, Michel Robert ^b  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b INSTITUT PASTEUR   (France)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^e Therapeutic Innovation Department   (France)

^f Biotem   (France)

^g ECDYSIS Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

A1HC38 ANTIBODY; B2 7 ANTIBODY; BLC3 ANTIBODY; BOTULINUM ANTISERUM; BOTULINUM TOXIN A; BOTULINUM TOXIN B; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; SEM120 IIIC1 ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BOTULISM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FEMALE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LD50; MALE; MOUSE; NONHUMAN; SURVIVAL RATE; ANIMAL; CLOSTRIDIUM BOTULINUM; HUMAN; IMMUNOLOGY; MACACA FASCICULARIS; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; BOTULINUM TOXINS, TYPE A; BOTULISM; CLOSTRIDIUM BOTULINUM; FEMALE; HUMANS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MICE; NEUTRALIZATION TESTS; SINGLE-CHAIN ANTIBODIES;

EID: 84987723981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161446     Document Type: Article

References (54)

1. Sobel J. Botulism. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005; 41: 1167-1173. Doi: 10.1086/444507
2. Fujinaga Y, Sugawara Y, Matsumura T. Uptake of botulinum neurotoxin in the intestine. Curr Top Microbiol Immunol. 2013; 364: 45-59. PMID: 23239348
3. Barash JR, Arnon SS. A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins. J Infect Dis. 2014; 209: 183-191. Doi: 10.1093/infdis/jit449 PMID: 24106296
4. Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular characterization of a novel botulinum neurotoxin type h gene. J Infect Dis. 2014; 209: 192-202. Doi: 10.1093/infdis/jit450 PMID: 24106295
5. Maslanka SE, Lúquez C, Dykes JK, Tepp WH, Pier CL, Pellett S, et al. A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin. J Infect Dis. 2016; 213: 379-385. Doi: 10.1093/infdis/jiv327 PMID: 26068781
6. Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013; 306: 124-146. Doi: 10.1016/j.tox.2013.02.006 PMID: 23435179
7. Weber JT, Hibbs RG, Darwish A, Mishu B, Corwin AL, Rakha M, et al. A massive outbreak of type E botulism associated with traditional salted fish in Cairo. J Infect Dis. 1993; 167: 451-454. PMID: 8421179
8. Hibbs RG, Weber JT, Corwin A, Allos BM, Abd el Rehim MS, Sharkawy SE, et al. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis Off Publ Infect Dis Soc Am. 1996; 23: 337-340.
9. Jalava K, Selby K, Pihlajasaari A, Kolho E, Dahlsten E, Forss N, et al. Two cases of food-borne botulism in Finland caused by conserved olives, October 2011. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2011; 16: 20034.
10. Pingeon JM, Vanbockstael C, Popoff MR, King LA, Deschamps B, Pradel G, et al. Two outbreaks of botulism associated with consumption of green olive paste, France, September 2011. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2011; 16: 20035.
11. Raphael BH, Shirey TB, Lúquez C, Maslanka SE. Distinguishing highly-related outbreak-associated Clostridium botulinum type A(B) strains. BMC Microbiol. 2014; 14: 192. Doi: 10.1186/1471-2180-14-192 PMID: 25031122
12. Gupta A, Sumner CJ, Castor M, Maslanka S, Sobel J. Adult botulism type F in the United States, 1981-2002. Neurology. 2005; 65: 1694-1700. Doi: 10.1212/01.wnl.0000187127.92446.4c PMID: 16344510
13. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000; 80: 717-766. PMID: 10747206
14. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001; 285: 1059-1070. PMID: 11209178
15. Froude JW, Stiles B, Pelat T, Thullier P. Antibodies for biodefense. mAbs. 2011; 3: 517-527. Doi: 10. 4161/mabs.3.6.17621 PMID: 22123065
16. Bozheyeva G, Kunakbayev Y, Yeleukenov D. Former Soviet Biological Weapons Facilities in Kazakhstan: Past, Present, and Future. Montrerey Inst Int Stud. 1999;Occasional Paper No. 1.
17. Broad WJ. SOWING DEATH: A special report.; How Japan Germ Terror Alerted World. The New York Times. 26 May 1998. Available: http://www.nytimes.com/1998/05/26/world/sowing-death-a-specialreport-how-japan-germ-terror-alerted-world.html. Accessed 22 Sep 2014.
18. Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A. 2005; 102: 9984-9989. Doi: 10.1073/pnas.0408526102 PMID: 15985558
19. Centers for Disease Control and Prevention (CDC). Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep. 2010; 59: 299. PMID: 20300057
20. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980; 69: 567-570. PMID: 7191633
21. Long SS. Infant botulism and treatment with BIG-IV (BabyBIG). Pediatr Infect Dis J. 2007; 26: 261-262. PMID: 17484226
22. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006; 354: 462-471. Doi: 10.1056/NEJMoa051926 PMID: 16452558
23. Rasetti-Escargueil C, Avril A, Chahboun S, Tierney R, Bak N, Miethe S, et al. Development of humanlike scFv-Fc antibodies neutralizing Botulinum toxin serotype B. mAbs. 2015; 7: 1161-1177. Doi: 10. 1080/19420862.2015.1082016 PMID: 26381852
24. Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, et al. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. mAbs. 2014; 6: 446-459. Doi: 10.4161/mabs.27773 PMID: 24492304
25. Avril A, Miethe S, Popoff MR, Mazuet C, Chahboun S, Rasetti-Escargueil C, et al. Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnol. 2015; 15: 86. Doi: 10.1186/s12896-015-0206-0 PMID: 26382731
26. Ahmadzadeh V, Farajnia S, Feizi MAH, Nejad RAK. Antibody humanization methods for development of therapeutic applications. Monoclon Antibodies Immunodiagn Immunother. 2014; 33: 67-73. Doi: 10. 1089/mab.2013.0080
27. Pelat T, Thullier P. Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies. mAbs. 2009; 1: 377-381. PMID: 20068407
28. Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol Baltim Md 1950. 2002; 169: 1119-1125.
29. Williams GT, Jolly CJ, Köhler J, Neuberger MS. The contribution of somatic hypermutation to the diversity of serum immunoglobulin: dramatic increase with age. Immunity. 2000; 13: 409-417. PMID: 11021538
30. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M-P, Thullier P. Germline humanization of a nonhuman primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol. 2008; 384: 1400-1407. Doi: 10.1016/j.jmb.2008.10.033 PMID: 18976662
31. Robert R, Streltsov VA, Newman J, Pearce LA, Wark KL, Dolezal O. Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment. Protein Sci Publ Protein Soc. 2010; 19: 299-308. Doi: 10.1002/pro.312
32. Pommié C, Levadoux S, Sabatier R, Lefranc G, Lefranc M-P. IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. J Mol Recognit JMR. 2004; 17: 17-32. Doi: 10.1002/jmr.647 PMID: 14872534
33. Whitelegg NR, Rees AR. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng. 2000; 13: 819-824. PMID: 11239080
34. Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol. 2003; 112: 563-570. PMID: 13679816
35. Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, et al. Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2007; 13: 4448-4455. Doi: 10.1158/1078-0432. CCR-06-1463 PMID: 17671129
36. Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, et al. A human scFv antibody generation pipeline for proteome research. J Biotechnol. 2011; 152: 159-170. Doi: 10.1016/j.jbiotec.2010.09.945 PMID: 20883731
37. Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol Baltim Md 1950. 2002; 169: 1119-1125.
38. Jones RGA, Alsop T-A, Hull R, Tierney R, Rigsby P, Holley J, et al. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon Off J Int Soc Toxinology. 2006; 48: 246-254. Doi: 10.1016/j.toxicon.2006.05.007
39. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 2002; 99: 11346-11350. Doi: 10.1073/pnas.172229899 PMID: 12177434
40. Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun. 2009; 77: 4305-4313. Doi: 10.1128/IAI.00405-09 PMID: 19651864
41. Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ, et al. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PloS One. 2008; 3: e3023. Doi: 10.1371/journal.pone.0003023 PMID: 18714390
42. Mazuet C, Dano J, Popoff MR, Créminon C, Volland H. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PloS One. 2010; 5: e12416. Doi: 10.1371/journal.pone.0012416 PMID: 20865035
43. Prigent J, Mazuet C, Boquet D, Lamourette P, Volland H, Popoff MR, et al. Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A. PloS One. 2010; 5: e13245. Doi: 10.1371/journal.pone.0013245 PMID: 20967241
44. Miethe S, Rasetti-Escargueil C, Avril A, Liu Y, Chahboun S, Korkeala H, et al. Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E. PloS One. 2015; 10: e0139905. Doi: 10.1371/journal.pone.0139905 PMID: 26440796
45. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25: 1605-1612. Doi: 10.1002/jcc.20084 PMID: 15264254
46. Jäger V, Büssow K, Wagner A, Weber S, Hust M, Frenzel A, et al. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol. 2013; 13: 52. Doi: 10.1186/1472-6750-13-52 PMID: 23802841
47. Sibéril S, Dutertre C-A, Boix C, Bonnin E, Ménez R, Stura E, et al. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett. 2006; 106: 111-118. Doi: 10.1016/j.imlet.2006.05.009 PMID: 16797726
48. Tsuji K, Steindler KA, Harrison SJ. Limulus amoebocyte lysate assay for detection and quantitation of endotoxin in a small-volume parenteral product. Appl Environ Microbiol. 1980; 40: 533-538. PMID: 6448582
49. Guttman A. On the separation mechanism of capillary sodium dodecyl sulfate-gel electrophoresis of proteins. Electrophoresis. 1995; 16: 611-616. PMID: 7588533
50. Szabo Z, Guttman A, Bones J, Karger BL. Rapid high-resolution characterization of functionally important monoclonal antibody N-glycans by capillary electrophoresis. Anal Chem. 2011; 83: 5329-5336. Doi: 10.1021/ac2007587 PMID: 21591710
51. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol. 2005; 351: 158-169. Doi: 10.1016/j.jmb.2005.06.003 PMID: 16002090
52. Schuck P, Minton AP. Kinetic analysis of biosensor data: elementary tests for self-consistency. Trends Biochem Sci. 1996; 21: 458-460. PMID: 9009825
53. Sesardic D, Jones RGA, Leung T, Alsop T, Tierney R. Detection of antibodies against botulinum toxins. Mov Disord Off J Mov Disord Soc. 2004; 19 Suppl 8: S85-91. Doi: 10.1002/mds.20021
54. Morineaux V, Mazuet C, Hilaire D, Enche J, Popoff MR. Characterization of botulinum neurotoxin type A subtypes by immunocapture enrichment and liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2015; 407: 5559-5570. Doi: 10.1007/s00216-015-8707-1 PMID: 26038189